METHODS	A total of 120 , ASA 1-2 , aged 18-75 years , patients were randomly assigned to receive one of the three groups : Group I ( control ) received placebo ( n = 40 ) , group II received 400 mg celecoxib orally ( n = 40 ) and group III received 40 mg parecoxib intravenously ( n = 40 ) .\